Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
22 Firms Get Approval for Lyrica Generics towards December Listing, Pfizer AG Included
The Ministry of Health, Labor and Welfare (MHLW) on August 17 approved a raft of generic drugs towards its next biannual generic listing in December, with 22 companies flocking to Pfizer’s flagship pain treatment Lyrica (pregabalin). All 22 companies received…
To read the full story
Related Article
- Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
March 8, 2021
- Authorized Generics for Lyrica, ComPlavin, Memary Dry Syrup Now Available
December 14, 2020
- Lyrica Faces Generic Debuts in Japan amid Patent Row: December Listing
December 10, 2020
- Pfizer Japan Takes Generic Contenders to Court over Lyrica Patent
August 18, 2020
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…